June 4, 2018—Myriad Genetics has signed a definitive agreement to acquire Counsyl for $375 million in cash and stock. Counsyl, founded in 2007, has generated more than $134 million in revenue in the past 12 months and performed more than 280,000 reproductive genetic tests.
“By offering Counsyl’s best-in-class reproductive testing products in conjunction with Myriad’s leading hereditary cancer tests, we are well positioned to be the premier women’s health genetic testing company,” Mark C. Capone, president and CEO of Myriad Genetics, said in a press release. “The Counsyl management team has a remarkable track record of success, and combining our commercial capabilities will lead to a threefold increase in physician reach for Counsyl’s reproductive tests.”
Counsyl will become a wholly owned subsidiary of Myriad once the transaction has closed, which is expected in early 2019. Counsyl’s products include the Foresight test for carrier screening, the Prelude test for prenatal screening, and the Reliant test, which screens for hereditary cancers.